Thrivent Financial for Lutherans Trims Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Thrivent Financial for Lutherans decreased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 3.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 624,888 shares of the biotechnology company's stock after selling 19,787 shares during the period. Thrivent Financial for Lutherans owned approximately 0.66% of Sarepta Therapeutics worth $78,042,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Innealta Capital LLC purchased a new stake in shares of Sarepta Therapeutics in the second quarter worth $31,000. New Covenant Trust Company N.A. bought a new stake in shares of Sarepta Therapeutics in the 1st quarter worth about $32,000. Huntington National Bank lifted its holdings in Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after buying an additional 175 shares in the last quarter. Nkcfo LLC purchased a new position in Sarepta Therapeutics during the 2nd quarter valued at about $43,000. Finally, Riggs Asset Managment Co. Inc. grew its position in shares of Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock worth $47,000 after buying an additional 75 shares during the last quarter. Institutional investors own 86.68% of the company's stock.

Insider Buying and Selling at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the company's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 14.99 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock traded up $0.13 during trading on Monday, hitting $104.67. The stock had a trading volume of 1,229,780 shares, compared to its average volume of 1,234,812. Sarepta Therapeutics, Inc. has a 12 month low of $78.67 and a 12 month high of $173.25. The business's 50-day moving average is $123.26 and its 200 day moving average is $132.19. The firm has a market cap of $10.00 billion, a price-to-earnings ratio of 83.74 and a beta of 0.81. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Analyst Upgrades and Downgrades

SRPT has been the subject of several analyst reports. Evercore ISI decreased their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a research note on Thursday, November 7th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Needham & Company LLC reaffirmed a "buy" rating and issued a $205.00 target price on shares of Sarepta Therapeutics in a report on Thursday, November 7th. Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They issued a "buy" rating and a $165.00 price target on the stock. Finally, UBS Group raised their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a "buy" rating in a research report on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics presently has an average rating of "Buy" and an average price target of $181.33.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.